Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene TSC1
Variant Q55Sfs*7
Impact List frameshift
Protein Effect loss of function - predicted
Gene Variant Descriptions TSC1 Q55Sfs*7 indicates a shift in the reading frame starting at amino acid 55 and terminating 7 residues downstream causing a premature truncation of the 1164 amino acid Tsc1 protein (UniProt.org). Q55Sfs*7 has not been characterized however, due to the effects of other truncation mutations downstream of Q55 (PMID: 11875047, PMID: 20547222), is predicted to lead to a loss of Tsc1 protein function.
Associated Drug Resistance
Category Variants Paths

TSC1 mutant TSC1 inact mut TSC1 Q55Sfs*7

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_000368.5
gDNA chr9:g.132927248delG
cDNA c.163delC
Protein p.Q55Sfs*7
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
XM_017015098.1 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
NM_001406593.1 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
XM_005272211 chr9:g.132927249delA c.162delT p.Q55Sfs*7 RefSeq GRCh38/hg38
NM_001406603.1 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
NM_001406604.1 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
NM_001406607.1 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
NM_001406606.1 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
NM_001406592.1 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
NM_001162426.2 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
XM_005272211.1 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
NM_001406613.1 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
XM_017015097 chr9:g.132927249delA c.162delT p.Q55Sfs*7 RefSeq GRCh38/hg38
XM_006717271 chr9:g.132927249delA c.162delT p.Q55Sfs*7 RefSeq GRCh38/hg38
XM_017015096.1 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
NM_001162426 chr9:g.132927249delA c.162delT p.Q55Sfs*7 RefSeq GRCh38/hg38
NM_001406600.1 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
XM_017015096 chr9:g.132927249delA c.162delT p.Q55Sfs*7 RefSeq GRCh38/hg38
XM_017015098 chr9:g.132927249delA c.162delT p.Q55Sfs*7 RefSeq GRCh38/hg38
XM_017015097.1 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
NM_001406601.1 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
NM_001406612.1 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
NM_000368.5 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
NM_001406594.1 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
XM_011518979.2 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
NM_001406610.1 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
NM_001406595.1 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
NM_001406605.1 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
XM_011518979 chr9:g.132927249delA c.162delT p.Q55Sfs*7 RefSeq GRCh38/hg38
NM_001406611.1 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
NM_001162427 chr9:g.132927249delA c.162delT p.Q55Sfs*7 RefSeq GRCh38/hg38
NM_001406602.1 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
NM_001162427.2 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
NM_001406598.1 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
XM_011518979.3 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
NM_001406608.1 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
NM_001162427.1 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
NM_000368.4 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
XM_006717271.1 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
NM_000368 chr9:g.132927249delA c.162delT p.Q55Sfs*7 RefSeq GRCh38/hg38
NM_001162426.1 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
NM_001406599.1 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
NM_001406609.1 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
NM_001406597.1 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38
NM_001406596.1 chr9:g.132927248delG c.163delC p.Q55Sfs*7 RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
TSC1 inact mut renal cell carcinoma predicted - sensitive Everolimus Clinical Study - Cohort Actionable In a retrospective analysis, 28% (12/43) of metastatic renal cell carcinoma patients who responded to rapalogs, Afinitor (everolimus) or Torisel (temsirolimus), harbored inactivating TSC1, TSC2 mutations and/or activating MTOR mutations, compared to 11% (4/36) in patients who did not respond to therapy (PMID: 26831717). 26831717
TSC1 inact mut clear cell renal cell carcinoma not applicable N/A Guideline Risk Factor Germline inactivating mutations in TSC1 result in tuberous sclerosis complex (TSC), which is associated with increased risk of developing clear cell renal cell carcinoma (NCCN.org). detail...
TSC1 inact mut islet cell tumor not applicable N/A Guideline Risk Factor Germline inactivating mutations in TSC1 result in tuberous sclerosis complex (TSC), which is associated with increased risk of developing pancreatic neuroendocrine tumors (NCCN.org). detail...
TSC1 inact mut perivascular epithelioid cell tumor predicted - sensitive Nab-rapamycin Phase II Actionable In a Phase II trial (AMPECT), Fyarro (nab-rapamycin) treatment in patients with perivascular epithelioid cell tumors (PEComas) resulted in partial response in 20% (1/5) of patients with TSC1 mutations, 89% (8/9) of patients with TSC2 mutations, and 9% (1/11) of patients without a TSC1 or TSC2 mutation (PMID: 34637337; NCT02494570). 34637337
TSC1 inact mut castration-resistant prostate carcinoma predicted - sensitive CC-115 + Enzalutamide Phase I Actionable In a Phase Ib trial, Xtandi (enzalutamide) plus CC-115 was safe and led to a PSA reduction >= 50% (PSA50) in 80% (32/40) and >=90% (PSA90) in 58% (23/40) of metastatic castration-resistant prostate cancer patients at 12 weeks, and patients with PIK3CA activating mutations or PTEN or TSC1/2 loss of function (n=16) achieved a PSA50, PSA90, and median radiographic progression-free survival of 94%, 63%, and 19.6 mo vs 67%, 47%, and 22.1 mo in PI3K pathway wild-type patients (n=15) (PMID: 37980367; NCT02833883). 37980367
TSC1 inact mut Advanced Solid Tumor no benefit Everolimus Phase II Actionable In a Phase II trial, Afinitor (everolimus) treatment resulted in limited activity with an objective response rate of 7% (2/30, 2 partial responses), stable disease in an additional 40% (12/30), a clinical benefit rate of 13% (4/30), a median progression-free survival of 2.3 months, and a median overall survival of 7.3 months in patients with advanced solid tumors harboring inactivating TSC1 or TSC2 mutations or activating MTOR mutations (PMID: 33727259; NCT02201212). 33727259
TSC1 inact mut renal cell carcinoma predicted - sensitive Temsirolimus Clinical Study - Cohort Actionable In a retrospective analysis, 28% (12/43) of metastatic renal cell carcinoma patients who responded to rapalogs, Afinitor (everolimus) or Torisel (temsirolimus), harbored inactivating TSC1, TSC2 mutations and/or activating MTOR mutations, compared to 11% (4/36) in patients who did not respond to therapy (PMID: 26831717). 26831717
TSC1 inact mut Advanced Solid Tumor predicted - sensitive Nab-rapamycin Clinical Study Actionable In a clinical study, Fyarro (nab-rapamycin) treatment in patients with advanced solid tumors harboring mutations in TSC1 or TSC2 led to a partial response in 4 patients, stable disease in 2 patients, and progressive disease in 1 patient of 7 enrolled patients (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 3111-3111; NCT03817515). detail...
TSC1 inact mut transitional cell carcinoma no benefit Sapanisertib Phase II Actionable In a Phase II trial, treatment with Sapanisertib (MLN0128) in metastatic urothelial carcinoma patients with either a TSC1 or TSC2 activating mutation (n=13) did not result in an objective response and led to a median overall survival of 3.4 months, and the trial was terminated early due to limited clinical activity and poor drug tolerability (Journal of Clinical Oncology 39, no. 6_suppl (February 20, 2021) 431-431; NCT03047213). detail...
TSC1 mutant bladder carcinoma sensitive Everolimus Phase II Actionable A retrospective study of a Phase II trial correlated increased sensitivity to the mTOR inhibitor Afinitor (everolimus) with TSC1 mutations in bladder cancer patients (PMID: 22923433). 22923433
TSC1 mutant renal cell carcinoma conflicting Everolimus Clinical Study - Cohort Actionable In a retrospective analysis, TSC1, TSC2, or MTOR mutation status was not associated with progression-free survival in renal cell carcinoma patients treated with Afinitor (everolimus) (PMID: 30327302). 30327302
TSC1 mutant renal cell carcinoma conflicting Everolimus Case Reports/Case Series Actionable In a clinical study, treatment with Afinitor (everolimus) or Torisel (temsirolimus) resulted in more partial responses (odds ratio = 0.08, p=0.030) in patients with renal cell carcinoma harboring mTOR pathway mutations, including MTOR (n=8), TSC1 (n=1), and TSC2 (n=2), than those without mutations (n=76) (PMID: 31335987). 31335987
TSC1 mutant subependymal giant cell astrocytoma predicted - sensitive Everolimus Phase III Actionable In a Phase III trial (EXIST-1), Afinitor (everolimus) treatment resulted in a 50% or more tumor reduction in 35% (27/78) of adult and pediatric patients diagnosed with tuberous sclerosis complex and had subependymal giant cell astrocytoma, compared to 0% (0/39) in the placebo group, 85% (99/117) of the patients harbored mutations in TSC1 and/or TSC2 (PMID: 23158522; NCT00789828). 23158522
TSC1 mutant renal cell carcinoma predicted - sensitive Temsirolimus Case Reports/Case Series Actionable In a clinical study, treatment with Afinitor (everolimus) or Torisel (temsirolimus) resulted in more partial responses (odds ratio = 0.08, p=0.030) in patients with renal cell carcinoma harboring mTOR pathway mutations, including MTOR (n=8), TSC1 (n=1), and TSC2 (n=2), than those without mutations (n=76) (PMID: 31335987). 31335987
TSC1 mutant lung non-small cell carcinoma no benefit Vistusertib Case Reports/Case Series Actionable In a Phase II trial (NLMT), Vistusertib (AZD2014) treatment did not result in a confirmed response (0/5) or durable clinical benefit (0/5) in patients with non-small cell lung cancer harboring TSC1 or TSC2 mutations, thus the cohort was closed due to futility (PMID: 32669708, NCT02664935). 32669708
TSC1 mutant hepatocellular carcinoma decreased response Sorafenib Clinical Study - Cohort Actionable In a clinical case study, Nexavar (sorafenib) treatment of patients with hepatocellular carcinoma harboring Mtor pathway mutations in PIK3CA, PTEN, TSC2, or TSC1 (n=12), resulted in a lower disease control rate (8.3% vs. 40.2%), shorter progression-free survival (1.9 months vs. 5.3 months) and shorter overall survival (10.4 months vs. 17.9 months) compared to patients without mutations in this pathway (n=67) (PMID: 30373752; NCT01775072). 30373752